Intas Pharma completes acquisition of UDENYCA biosimilar for $558 million

Intas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. This acquisition strengthens Intas's position as a global leader in pegfilgrastim. Accord BioPharma, Intas's U.S. specialty business, will continue commercializing UDENYCA to reduce infection risk in cancer patients undergoing myelosuppressive chemotherapy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tpuhbM4
via IFTTT